| |
| Device | MyChoice CDx® |
| Generic Name | Cancer-related germline gene mutation detection system |
| Applicant | Myriad Genetic Laboratories, Inc. 320 Wankara Way Salt Lake City, UT 84108 |
| PMA Number | P190014 |
| Supplement Number | S007 |
| Date Received | 10/17/2022 |
| Decision Date | 11/14/2022 |
| Product Code |
PJG |
| Advisory Committee |
Pathology |
| Supplement Type | Special (Immediate Track) |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approved removal of the companion diagnostic indication for MyChoice® CDx to identify patients with ovarian, fallopian tube, or primary peritoneal cancer with homologous recombination deficiency (HRD) positive status for treatment with Zejula (niraparib). |